The estimated Net Worth of G. Walmsley Graham is at least $38.3 Milione dollars as of 8 December 2023. Mr. Graham owns over 100,000 units of Akero Therapeutics Inc stock worth over $20,496,000 and over the last 5 years he sold AKRO stock worth over $17,448,750. In addition, he makes $376,579 as Non-Executive Independent Director at Akero Therapeutics Inc.
Sign up
Mr. Walmsley AKRO stock SEC Form 4 insiders trading
Graham has made over 10 trades of the Akero Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of AKRO stock worth $1,983,000 on 8 December 2023.
The largest trade he's ever made was selling 1,175,000 units of Akero Therapeutics Inc stock on 12 September 2023 worth over $17,448,750. On average, Graham trades about 172,599 units every 61 days since 2019. As of 8 December 2023 he still owns at least 800,000 units of Akero Therapeutics Inc stock.
You can see the complete history of Mr. Graham stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Graham Walmsley biography
Graham Walmsley M.D. Ph.D. serves as Non-Executive Independent Director of the Company. Dr. Walmsley has served as a member of our board of directors since June 2018. Dr. Walmsley currently serves as a Principal at Versant Ventures, where he has been employed since July 2016 after he received his Ph.D. from Stanford University School of Medicine and where he specializes in healthcare and biotechnology investments. At Versant, Dr. Walmsley has contributed to the deployment of capital into early and mid-stage private biotechnology companies across multiple funds. In addition, Dr. Walmsley served as Head of Business Development at Jecure Therapeutics, Inc., a biotechnology company, since June 2017 through its acquisition by Roche/Genentech in November 2018. Dr. Walmsley currently serves as a board observer for Turnstone Biologics Inc., an immuno-oncology company, BlueRock Therapeutics, LP, an engineered cell therapy company and Aligos Therapeutics, Inc., a biotechnology company. He was previously a board observer for CODA Biotherapeutics, Inc., a biopharmaceutical company. Dr. Walmsley received a B.A. in molecular and cell biology from the University of California, Berkeley and an M.D. and Ph.D. from Stanford University School of Medicine.
What is the salary of Graham Walmsley?
As the Non-Executive Independent Director of Akero Therapeutics Inc, the total compensation of Graham Walmsley at Akero Therapeutics Inc is $376,579. There are 11 executives at Akero Therapeutics Inc getting paid more, with Andrew Cheng having the highest compensation of $5,431,810.
How old is Graham Walmsley?
Graham Walmsley is 33, he's been the Non-Executive Independent Director of Akero Therapeutics Inc since 2018. There are 14 older and no younger executives at Akero Therapeutics Inc. The oldest executive at Akero Therapeutics Inc is Dr. Timothy Rolph, 67, who is the Co-Founder & Chief Scientific Officer.
What's Graham Walmsley's mailing address?
G's mailing address filed with the SEC is C/O LOGOS GLOBAL MANAGEMENT LP, 1 LETTERMAN DRIVE, BLDG. C, STE C3-350, SAN FRANCISCO, CA, 94129.
Insiders trading at Akero Therapeutics Inc
Over the last 5 years, insiders at Akero Therapeutics Inc have traded over $146,260,704 worth of Akero Therapeutics Inc stock and bought 4,870,000 units worth $104,250,550 . The most active insiders traders include Group, Llc Green Jeremy Red..., Trust Blue Horizon Enterpri... e G. Walmsley Graham. On average, Akero Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,642,344. The most recent stock trade was executed by Jonathan Young on 3 September 2024, trading 5,000 units of AKRO stock currently worth $133,600.
What does Akero Therapeutics Inc do?
akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
What does Akero Therapeutics Inc's logo look like?
Complete history of Mr. Graham stock trades at Akero Therapeutics Inc, Olema Pharmaceuticals e ALX Oncology
Akero Therapeutics Inc executives and stock owners
Akero Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Andrew Cheng,
President, Chief Executive Officer, Director -
William White,
Chief Financial Officer, Executive Vice President and Head of Corporate Development -
Timothy Rolph,
Co-Founder, Chief Scientific Officer -
Jonathan Young,
Co-Founder, Chief Operating Officer, Executive Vice President -
Dr. Andrew Cheng,
Pres, CEO & Director -
Dr. Timothy Rolph,
Co-Founder & Chief Scientific Officer -
Dr. Jonathan M. Young,
Co-Founder, Exec. VP, COO & Sec. -
William R. White J.D.,
Exec. VP, CFO, Treasurer & Head of Corp. Devel. -
Mark Iwicki,
Independent Non-Executive Chairman of the Board -
Kevin Bitterman,
Non-Executive Independent Director -
Seth Harrison,
Non-Executive Independent Director -
Graham Walmsley,
Non-Executive Independent Director -
Kitty Yale,
Chief Development Officer -
Jane Henderson,
Non-Executive Independent Director -
Tomas Heyman,
Independent Director -
Kitty Yale,
Exec. VP & Chief Devel. Officer -
John J. Schembri,
VP of Fin. & Controller -
Venture Fund Xi, L.P. Atlas,
10% owner -
Trust Blue Horizon Enterpri...,
-
Venture Capital Vi, L.P.Ver...,
-
Group, Llc Green Jeremy Red...,
-
Global Strategic Fund Ii L....,
-
Venture Fund Xi, L.P.Atlas ...,
-
Aaron Royston,
Director -
Venture Capital Vi, L.P. Ve...,
10% owner -
Life Science Ventures, L.P....,
-
Venture Fund Xi, L.P.Atlas ...,
-
Venture Opportunity Fund I,...,
10% owner -
Chou Judy,
-
Catriona Yale,
Chief Development Officer -
Yuan Xu,
-
Scott A. Gangloff,
Chief Technology Officer -
Patrick Lamy,
Senior VP, Commercial Strategy